ECSP10010430A - Ciertas Entidades Químicas, Composiciones y Procedimientos - Google Patents

Ciertas Entidades Químicas, Composiciones y Procedimientos

Info

Publication number
ECSP10010430A
ECSP10010430A EC2010010430A ECSP10010430A ECSP10010430A EC SP10010430 A ECSP10010430 A EC SP10010430A EC 2010010430 A EC2010010430 A EC 2010010430A EC SP10010430 A ECSP10010430 A EC SP10010430A EC SP10010430 A ECSP10010430 A EC SP10010430A
Authority
EC
Ecuador
Prior art keywords
skeletal
muscle
chemical entities
certain chemical
procedures
Prior art date
Application number
EC2010010430A
Other languages
English (en)
Spanish (es)
Inventor
Bradley Paul Morgan
Alex Muci
Zhe Yang
Scott Collibee
Jiancho Wang
Jeff Gardina
Luke W Ashcraft
Brian Stoltz
Gustave Bergnes
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of ECSP10010430A publication Critical patent/ECSP10010430A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Medicinal Preparation (AREA)
EC2010010430A 2008-02-04 2010-08-27 Ciertas Entidades Químicas, Composiciones y Procedimientos ECSP10010430A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2606708P 2008-02-04 2008-02-04

Publications (1)

Publication Number Publication Date
ECSP10010430A true ECSP10010430A (es) 2011-02-28

Family

ID=40952391

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2010010430A ECSP10010430A (es) 2008-02-04 2010-08-27 Ciertas Entidades Químicas, Composiciones y Procedimientos
EC2010010432A ECSP10010432A (es) 2008-02-04 2010-08-30 Método para la mejora de la recuperación de hidrocarburos pesados

Family Applications After (1)

Application Number Title Priority Date Filing Date
EC2010010432A ECSP10010432A (es) 2008-02-04 2010-08-30 Método para la mejora de la recuperación de hidrocarburos pesados

Country Status (18)

Country Link
US (2) US7989469B2 (enExample)
EP (1) EP2244711A4 (enExample)
JP (1) JP2011510985A (enExample)
KR (1) KR20100119773A (enExample)
CN (1) CN101983061A (enExample)
AR (1) AR072242A1 (enExample)
AU (1) AU2009210787A1 (enExample)
BR (1) BRPI0907502A2 (enExample)
CA (1) CA2713864A1 (enExample)
CL (1) CL2009000246A1 (enExample)
CO (1) CO6290673A2 (enExample)
EA (1) EA201001224A1 (enExample)
EC (2) ECSP10010430A (enExample)
IL (1) IL207367A0 (enExample)
MX (1) MX2010008518A (enExample)
TW (1) TW200946524A (enExample)
WO (1) WO2009099594A1 (enExample)
ZA (1) ZA201005780B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US7989469B2 (en) * 2008-02-04 2011-08-02 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
US8927572B2 (en) 2011-07-09 2015-01-06 Xuanzhu Pharma Co., Ltd. Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof
US10272082B2 (en) 2011-07-13 2019-04-30 Cytokinetics, Inc. Combination ALS therapy
CN104395458A (zh) * 2012-04-11 2015-03-04 赛特凯恩蒂克公司 改善对骨骼肌疲劳的抵抗力
PL3137622T3 (pl) 2014-04-29 2022-05-09 Cytokinetics, Inc. Sposoby redukowania spadku pojemności życiowej
TW201927738A (zh) * 2017-12-14 2019-07-16 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
TWI794369B (zh) * 2017-12-14 2023-03-01 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
CA3141571A1 (en) * 2019-05-28 2020-12-03 Mankind Pharma Ltd. 1h-imidazo[4,5-b]pyridin-2(3h)-one compounds and derivatives for inhibition of janus kinase 1
CN117355522A (zh) * 2021-05-06 2024-01-05 爱智药人工智能有限公司 PKC-theta调节剂
CN118702622A (zh) * 2024-08-30 2024-09-27 阜新达得利化工股份有限公司 一种3-溴-2-氰基吡啶的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
WO2004043913A2 (en) * 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
US20060148805A1 (en) * 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
US20050250794A1 (en) * 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
JP2007529422A (ja) * 2004-01-29 2007-10-25 エリクシアー ファーマシューティカルズ， インコーポレイテッド 抗ウイルス治療
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1959962A2 (en) * 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
KR101410453B1 (ko) * 2006-08-02 2014-06-27 싸이토키네틱스, 인코포레이티드 소정의 화학 물질, 조성물 및 방법
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
MX2009004077A (es) * 2006-10-19 2009-05-05 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
US7851484B2 (en) * 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7989469B2 (en) * 2008-02-04 2011-08-02 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US7998976B2 (en) * 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US8877772B2 (en) 2008-11-25 2014-11-04 University Of Rochester Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors

Also Published As

Publication number Publication date
TW200946524A (en) 2009-11-16
MX2010008518A (es) 2010-11-10
EP2244711A1 (en) 2010-11-03
AU2009210787A1 (en) 2009-08-13
EP2244711A4 (en) 2011-08-24
WO2009099594A1 (en) 2009-08-13
CN101983061A (zh) 2011-03-02
BRPI0907502A2 (pt) 2019-01-15
CO6290673A2 (es) 2011-06-20
US7989469B2 (en) 2011-08-02
JP2011510985A (ja) 2011-04-07
CA2713864A1 (en) 2009-08-13
ECSP10010432A (es) 2011-01-31
US20090253737A1 (en) 2009-10-08
EA201001224A1 (ru) 2011-08-30
KR20100119773A (ko) 2010-11-10
CL2009000246A1 (es) 2009-06-26
IL207367A0 (en) 2010-12-30
ZA201005780B (en) 2011-04-28
AR072242A1 (es) 2010-08-18
US20110312975A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
ECSP10010430A (es) Ciertas Entidades Químicas, Composiciones y Procedimientos
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CL2008002916A1 (es) Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros.
CL2008001632A1 (es) Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
CO6362020A2 (es) Mutantes fgf21 y uso de los mismos
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112015024846A2 (pt) composições para utilização no estímulo do crescimento ósseo
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
EA201491666A1 (ru) Способы повышения устойчивости скелетных мышц к утомлению
PE20150954A1 (es) Proteinas del dominio de soporte basadas en fibronectina que se fijan a miostatina
MX2011011958A (es) Metodos para el tratamiento de trastornos metabolicos utilizando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales.
UY30454A1 (es) Moduladores tiazolopirimidina de trpv1
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
BR112014005358A2 (pt) composição para alívio da dor, compreendendo um agonista seletivo de trpv1, e a sua fabricação e utilização
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
UY30468A1 (es) Compuestos quimicos.
MX2010001692A (es) Ciertas entidades quimicas, composiciones y metodos.
UY31540A1 (es) Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
EA201891754A1 (ru) Композиции гиалуроновой кислоты, включающие мепивакаин
BR112015013046A2 (pt) composição comestível, método de redução da amplitude do pico de glicose pós-prandial no sangue ou resposta glicêmica em uma pessoa diabética ou não diabética, método para tratar uma pessoa em necessidade deste para diabetes tipo 2 e uso de uma composição
PH12014502711A1 (en) Compositions and methods for enhancing mobilization and proliferation of blastomere-like stem cells
BR112015012581A2 (pt) análogos de ravioli e métodos para fazer tais análogos
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
BR112016007487A2 (pt) composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica